Target intelligence / Profile preview

E3 ubiquitin-protein ligase TRIM52 (TRIM52)

Target
TRIM52
Molecular classification
Enzyme, E3 ubiquitin ligase, Tripartite motif (TRIM) family
01

Overview

E3 ubiquitin-protein ligase TRIM52 is a member of the tripartite motif (TRIM) family of proteins, characterized by a RING domain that confers E3 ligase activity, and unique sequence features distinguishing it from other TRIM family members[1][2]. TRIM52 participates in the ubiquitin-proteasome system, targeting specific proteins—including itself—for degradation; it is unusually unstable and tightly regulated by multiple giant E3 ligases (such as BIRC6, HUWE1, and UBR4/KCMF1)[1][4]. TRIM52 maintains genomic DNA integrity by limiting the accumulation of topoisomerase 2 DNA adducts and acts to prevent cell cycle arrest via the p53 pathway—loss of TRIM52 results in increased DNA lesions, p53 activation, and decreased cell fitness[1]. It is upregulated in various cancers, where it contributes to cell proliferation and survival in a context-dependent manner[1][3]. In addition to its role in cell division and DNA repair, TRIM52 can act as an antiviral factor, such as inhibiting Japanese Encephalitis Virus replication by targeting viral proteins for degradation via the ubiquitin-proteasome system[2]. Its functions are essential in some cancer cell backgrounds and may represent a potential, although as-yet untargeted, therapeutic vulnerability[3].

Other names
RING finger protein 102RNF102Tripartite motif-containing protein 52
02

Mechanism of action

Ubiquitination and proteasomal degradation of substrate proteins; mechanism for drugs would be inhibition or modulation of E3 ligase activity, but no drugs currently reported

03

Biological functions

Ubiquitin-mediated protein degradationMaintenance of genome integrityCell cycle controlDNA damage responseRegulation of cell proliferationAntiviral response
04

Disease associations

CancerInfection (including antiviral response)Other (may relate to stress or cell cycle arrest)
05

Safety considerations

Potential for cell cycle arrest and compromised cell fitness if inhibitedpossible impact on DNA repair and genome stabilitycell context-specific dependency
06

Biomarkers

Overexpression in certain cancersp53 activation (as evidence of genomic stress or TRIM52 loss)

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase TRIM52 (TRIM52).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM52 (TRIM52).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call